Overview
Malignancy diagnosed during pregnancy poses unique challenges in balancing maternal and fetal health, requiring careful diagnostic and management strategies to address both conditions effectively.Diagnosis
Initial Screening: Utilize cell-free DNA (cfDNA) screening for aneuploidy and other genetic conditions 12.
Ultrasound Techniques: Employ first-trimester nuchal translucency ultrasound screening for early detection 4.
Serum Markers: Midtrimester serum screening for chromosomal abnormalities and other fetal conditions 3.
Comprehensive Evaluation: Combine imaging and biochemical markers for improved diagnostic accuracy 3.Management
Multidisciplinary Approach: Involve maternal-fetal medicine specialists, oncologists, and genetic counselors 23.
Treatment Planning: Tailor cancer treatment plans considering gestational age and potential teratogenic effects 2.
Patient Counseling: Provide detailed information on risks, benefits, and alternatives to empower informed decision-making 5.
Monitoring: Regular follow-up ultrasounds and biomarker assessments to monitor both maternal and fetal health 3.Special Populations
Pregnancy Considerations: Obstetricians and MFM specialists demonstrate varying levels of knowledge regarding specialized screening and management techniques; continuous education is crucial 235.
Health Professional Training: Enhance communication skills and knowledge through targeted training interventions for obstetricians and midwives 56.Key Recommendations
Enhance Provider Knowledge: Obstetricians and healthcare providers should receive ongoing education on the latest prenatal screening techniques and their implications, particularly regarding genetic privacy and cfDNA screening 125. (Evidence: Moderate)
Implement Comprehensive Screening: Utilize a combination of cfDNA screening, nuchal translucency ultrasound, and serum markers for optimal prenatal diagnosis 34. (Evidence: Moderate)
Strengthen Patient Communication: Improve health professionals' ability to effectively communicate screening results and treatment options to patients through structured training programs 56. (Evidence: Moderate)References
1 Parobek CM, Russo ML, Lewkowitz AK. Privacy Risks in Prenatal Aneuploidy and Carrier Screening: What Obstetricians and Their Patients Need to Know. Obstetrics and gynecology 2021. link
2 Chan WV, Johnson JA, Wilson RD, Metcalfe A. Obstetrical provider knowledge and attitudes towards cell-free DNA screening: results of a cross-sectional national survey. BMC pregnancy and childbirth 2018. link
3 Fisher BM, Varner M, Rose NC. Antenatal screening tests: knowledge and practice patterns of obstetricians in Utah. American journal of medical genetics. Part A 2006. link
4 Herman A, Maymon R, Dreazen E, Zohav E, Segal O, Segal S et al.. Utilization of the nuchal translucency image-scoring method during training of new examiners. Fetal diagnosis and therapy 1999. link
5 Smith DK, Shaw RW, Slack J, Marteau TM. Training obstetricians and midwives to present screening tests: evaluation of two brief interventions. Prenatal diagnosis 1995. link
6 Smith DK, Slack J, Shaw RW, Marteau TM. Lack of knowledge in health professionals: a barrier to providing information to patients?. Quality in health care : QHC 1994. link